<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Myelofibrosis</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            background-color: #f5f5f5;
            color: #333;
            padding: 20px;
            line-height: 1.6;
            max-width: 900px;
            margin: auto;
        }
        h1, h2 {
            color: #004080;
        }
        h1 {
            text-align: center;
        }
        ul {
            background: #fff;
            padding: 15px;
            border-radius: 10px;
            box-shadow: 2px 2px 10px rgba(0,0,0,0.1);
        }
        li {
            margin-bottom: 10px;
        }
        .section {
            background: #e6f7ff;
            padding: 15px;
            border-radius: 10px;
            margin-bottom: 20px;
        }
    </style>
</head>
<body>
    <h1>Myelofibrosis</h1>

    <div class="section">
        <h2>1. Overview of Myelofibrosis (MF)</h2>
        <ul>
            <li><strong>Definition:</strong> A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, extramedullary hematopoiesis, and cytopenias.</li>
            <li><strong>Types:</strong>
                <ul>
                    <li><strong>Primary Myelofibrosis (PMF):</strong> Develops without a prior hematologic disorder.</li>
                    <li><strong>Secondary Myelofibrosis:</strong> Evolves from Essential Thrombocythemia (ET) or Polycythemia Vera (PV).</li>
                </ul>
            </li>
        </ul>
    </div>

    <div class="section">
    <h2>2. Early (Prefibrotic) vs. Overt Myelofibrosis</h2>
    <ul>
        <li><strong>Early/Prefibrotic Myelofibrosis:</strong>
            <ul>
                <li>Minimal bone marrow fibrosis (Grade 0-1)</li>
                <li>Increased atypical megakaryocytes and granulocytic proliferation</li>
                <li>Patients may be asymptomatic or present with mild anemia or thrombocytosis</li>
            </ul>
        </li>
        <li><strong>Overt Myelofibrosis:</strong>
            <ul>
                <li>Advanced fibrosis (Grade 2-3) with significant collagen deposition</li>
                <li>Cytopenias, extramedullary hematopoiesis, and constitutional symptoms</li>
                <li>Includes <strong>Primary (Overt) MF</strong> and <strong>Secondary (Post-ET/Post-PV MF)</strong></li>
            </ul>
        </li>
    </ul>
</div>


    <div class="section">
        <h2>3. Blast Phase Transformation</h2>
        <ul>
            <li>Occurs when MF progresses to Acute Myeloid Leukemia (AML) (blast cells ≥20%).</li>
            <li><strong>Phases:</strong>
                <ul>
                    <li>Chronic phase: Blasts &lt;10%</li>
                    <li>Accelerated phase: Blasts 10-19%</li>
                    <li>Blast phase: Blasts ≥20%</li>
                </ul>
            </li>
        </ul>
    </div>

    <div class="section">
        <h2>4. Mutational Landscape in Myelofibrosis</h2>
        <ul>
            <li>Standard Testing: Detects JAK2, CALR, MPL mutations.</li>
            <li>Extended Genetic Testing (NGS Panel): Identifies additional mutations affecting prognosis.</li>
        </ul>
    </div>

    <div class="section">
        <h2>5. DIPSS (Dynamic International Prognostic Scoring System)</h2>
        <ul>
            <li><strong>Risk Factors:</strong> Age > 65, constitutional symptoms, hemoglobin < 10 g/dL, leukocytes > 25 x 10⁹/L, circulating blasts ≥1%.</li>
            <li><strong>Risk Categories:</strong>
                <ul>
                    <li>Low risk: 0 points</li>
                    <li>Intermediate-1: 1-2 points</li>
                    <li>Intermediate-2: 3-4 points</li>
                    <li>High risk: 5-6 points</li>
                </ul>
            </li>
            <li><strong>Clinical Implications:</strong>
                <ul>
                    <li><strong>High-risk MF:</strong> Shorter survival (median 2-4 years), increased need for aggressive treatment (e.g., stem cell transplantation).</li>
                    <li><strong>Low-risk MF:</strong> Longer survival (median 5-15 years), may require less aggressive management.</li>
                </ul>
            </li>
        </ul>
    </div>

    <div class="section">
        <h2>6. Treatment Considerations</h2>
        <ul>
            <li><strong>Early/Prefibrotic MF:</strong>
                <ul>
                    <li>Observation or symptom-directed therapy.</li>
                    <li>Consideration for JAK inhibitors in symptomatic patients.</li>
                </ul>
            </li>
            <li><strong>Overt MF:</strong>
                <ul>
                    <li>JAK inhibitors (e.g., ruxolitinib, fedratinib) for symptom control.</li>
                    <li>Allogeneic stem cell transplantation for eligible high-risk patients.</li>
                    <li>Supportive care: Blood transfusions, erythropoiesis-stimulating agents (ESAs), thrombopoietin receptor agonists.</li>
                </ul>
            </li>
            <li><strong>Blast Phase MF:</strong>
                <ul>
                    <li>AML-directed therapy (e.g., hypomethylating agents, intensive chemotherapy, or targeted therapy).</li>
                    <li>Stem cell transplantation if feasible.</li>
                </ul>
            </li>
        </ul>
    </div>
</body>
</html>
